Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies.

1] Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA. [2] Stanford Cardiovascular Institute, Stanford School of Medicine, Stanford, California, USA. [3] Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, California, USA. [4].
Nature medicine (Impact Factor: 28.05). 08/2013; 19(8):998-1004. DOI: 10.1038/nm.3267
Source: PubMed

ABSTRACT Human pluripotent stem cells (PSCs) are a leading candidate for cell-based therapies because of their capacity for unlimited self renewal and pluripotent differentiation. These advances have recently culminated in the first-in-human PSC clinical trials by Geron, Advanced Cell Technology and the Kobe Center for Developmental Biology for the treatment of spinal cord injury and macular degeneration. Despite their therapeutic promise, a crucial hurdle for the clinical implementation of human PSCs is their potential to form tumors in vivo. In this Perspective, we present an overview of the mechanisms underlying the tumorigenic risk of human PSC-based therapies and discuss current advances in addressing these challenges.

Download full-text


Available from: Mahendra Surendra Rao, Dec 26, 2013